Galmed Pharmaceuticals

Company snapshot

Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Our lead compound, Aramchol™, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study. We are also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino acid synthetic peptid

• 13 active pipeline program(s) linked via ClinicalTrials.gov.
• 11 US patent(s) indexed to this assignee profile.
• 13 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Galmed Pharmaceuticals. Not investment advice.

• Peer + 0 momentum

  CORCEPT THERAPEUTICS

  TA overlap score 33.4

• Peer + 0 momentum

  Madrigal Pharmaceuticals EU

  TA overlap score 33.2

• Peer + 0 momentum

  Galectin Therapeutics

  TA overlap score 22.4

• Peer + 0 momentum

  Chemomab Therapeutics

  TA overlap score 21.2

Recent activity

Latest pipeline, patent, and corporate events for Galmed Pharmaceuticals.

1. Jun 5, 2026 Clinical update

   A study to compare two different aramchol formulations in healthy volunteers. — Phase 1

2. Jun 5, 2026 Clinical update

   mFOLFOX6 + BIBF 1120 — Phase 2

3. Jun 5, 2026 Clinical update

   Aramchol — Phase 2

4. Jun 5, 2026 Clinical update

   Aramchol free acid tablet 600mg, single dose — Phase 1

5. Jun 5, 2026 Clinical update

   Aramchol free acid — Phase 3

View all clinical trial activity →

• What is Galmed Pharmaceuticals?

  Galmed Pharmaceuticals is a pharma organization headquartered in Tel Aviv, USA. It trades on NYSE under ticker GLMD. Primary therapeutic focus areas include Fatty Liver, Inflammatory Disease, Nonalcoholic Steatohepatitis (NASH), Hepatic Impairment, Gallstones. NovaPharmaNews link

• Is Galmed Pharmaceuticals publicly traded?

  Yes. Galmed Pharmaceuticals is listed with ticker GLMD on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Galmed Pharmaceuticals develop or market?

  We link 5 drug profile(s) where Galmed Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/galmed-pharmaceuticals#company-drugs.

• What are the latest developments for Galmed Pharmaceuticals?

  In the last 12 months our linked public records show 13 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Galmed Pharmaceuticals focus on?

  Galmed Pharmaceuticals focuses on Fatty Liver, Inflammatory Disease, Nonalcoholic Steatohepatitis (NASH) based on our analysis of their pipeline programs and drug development activities.